Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico-ko ikertzaileekin lankidetzan egindako argitalpenak (1)

2019

  1. P65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma

    Journal of Experimental and Clinical Cancer Research, Vol. 38, Núm. 1